Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 15, 2019 07:00 ET | Source: WindMIL Therapeutics

WindMIL Therapeutics and University of California, Irvine Announce Collaboration to Collect Bone Marrow from Patients with Gliomas to Develop Marrow Infiltrating Lymphocytes (MILs™)

BALTIMORE and PHILADELPHIA and IRVINE, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics and the University of California, Irvine (UCI) today announced that the first patients have...
September 30, 2019 07:00 ET | Source: WindMIL Therapeutics

WindMIL Therapeutics to Present at 2019 Cell & Gene Meeting on the Mesa

BALTIMORE, Md. and PHILADELPHIA, Sept. 30, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy,...
September 09, 2019 07:00 ET | Source: WindMIL Therapeutics

WindMIL Therapeutics Appoints Urvashi Patel, PhD, as Vice President of Regulatory and Quality Systems

BALTIMORE and PHILADELPHIA, Sept. 09, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, has...
July 09, 2019 07:00 ET | Source: WindMIL Therapeutics

WindMIL Therapeutics and University of Michigan Announce Collaboration to Collect Bone Marrow from Patients with Head and Neck Cancer to Develop Marrow Infiltrating Lymphocytes (MILs™)

BALTIMORE and PHILADELPHIA and ANN ARBOR, Mich., July 09, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics (WindMIL) and the University of Michigan Rogel Cancer Center today announced that the first...
June 25, 2019 07:00 ET | Source: WindMIL Therapeutics

WindMIL Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 2 Study of Marrow Infiltrating Lymphocytes (MILs™) in Non-Small Cell Lung Cancer

BALTIMORE and PHILADELPHIA, June 25, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, announced...
April 25, 2019 07:00 ET | Source: WindMIL Therapeutics

WindMIL Therapeutics Appoints Donald J. Hayden, Jr., as CEO

BALTIMORE, Md., April 25, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, has announced the...
April 17, 2019 07:00 ET | Source: WindMIL Therapeutics

WindMIL Therapeutics Announces Promotions to Newly Created Leadership Roles as Part of Continued Growth

BALTIMORE, April 17, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, has announced the promotions...
March 25, 2019 08:00 ET | Source: WindMIL Therapeutics

WindMIL Therapeutics Appoints Sanjin Zvonić, PhD, as Vice President of Process Science and Manufacturing

BALTIMORE, March 25, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, has announced the...
December 20, 2018 07:00 ET | Source: WindMIL Therapeutics

WindMIL Therapeutics Expands Leadership Team and Opens Office in Philadelphia

BALTIMORE, Dec. 20, 2018 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, has announced the...
December 03, 2018 07:00 ET | Source: WindMIL Therapeutics

WindMIL Therapeutics Announces Preclinical Data Demonstrating Marrow-Infiltrating Lymphocytes’ Potential as CAR-Modified T Cell Therapy Platform

BALTIMORE, Dec. 03, 2018 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, yesterday announced...